Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2018
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Metabotropic Glutamate Receptor 3 - Pipeline Review, H2 2018'; Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Metabotropic glutamate receptor 3 is a G protein-coupled receptor encoded by the GRM3 gene. L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors.
Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. mGluR3 is expressed by glia and neurons in many brain regions and has a predominantly presynaptic distribution, consistent with its role as an inhibitory auto receptor and heteroceptor. mGluR3 are coupled to Gi/o which inhibits adenylyl cyclase, decreasing the formation of cAMP.
The report 'Metabotropic Glutamate Receptor 3 - Pipeline Review, H2 2018' outlays comprehensive information on the Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Report covers products from therapy areas Central Nervous System and Oncology which include indications Depression, Glioma, Pervasive Developmental Disorder (PDD), Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Impairment, Neurodegenerative Diseases, Parkinson's Disease, Schizophrenia, Smoking Addiction and Treatment Resistant Depression.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Metabotropic Glutamate Receptor 3 - Pipeline Review, H2 2018'; Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Metabotropic glutamate receptor 3 is a G protein-coupled receptor encoded by the GRM3 gene. L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors.
Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. mGluR3 is expressed by glia and neurons in many brain regions and has a predominantly presynaptic distribution, consistent with its role as an inhibitory auto receptor and heteroceptor. mGluR3 are coupled to Gi/o which inhibits adenylyl cyclase, decreasing the formation of cAMP.
The report 'Metabotropic Glutamate Receptor 3 - Pipeline Review, H2 2018' outlays comprehensive information on the Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Report covers products from therapy areas Central Nervous System and Oncology which include indications Depression, Glioma, Pervasive Developmental Disorder (PDD), Anxiety Disorders, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Impairment, Neurodegenerative Diseases, Parkinson's Disease, Schizophrenia, Smoking Addiction and Treatment Resistant Depression.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)
- The report reviews Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Overview
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Aevi Genomic Medicine Inc
AstraZeneca Plc
Denovo Biopharma LLC
Domain Therapeutics SA
Eli Lilly and Co
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drug Profiles
AEVI-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-8529 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-010991 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-011088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasoracetam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3020371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-341495 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pomaglumetad methionil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize mGLUR3 for Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Modulate mGlu3 Receptor for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0092273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0650786 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Dormant Products
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Discontinued Products
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Product Development Milestones
Featured News & Press Releases
Jul 19, 2018: Aevi Genomic Medicine Announces Novel Co-crystal Version of AEVI-001
Jun 12, 2018: Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD
May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001
Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder
Oct 18, 2016: Domain Therapeutics and Medicxi launch Mavalon Therapeutics, aimed at halting the progression of Parkinson’s disease
Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD
Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson’s disease with renewed support by The Michael J. Fox Foundation
Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results
Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study
Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Overview
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Aevi Genomic Medicine Inc
AstraZeneca Plc
Denovo Biopharma LLC
Domain Therapeutics SA
Eli Lilly and Co
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drug Profiles
AEVI-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-8529 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-010991 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-011088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasoracetam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3020371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-341495 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pomaglumetad methionil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize mGLUR3 for Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Modulate mGlu3 Receptor for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0092273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0650786 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Dormant Products
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Discontinued Products
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Product Development Milestones
Featured News & Press Releases
Jul 19, 2018: Aevi Genomic Medicine Announces Novel Co-crystal Version of AEVI-001
Jun 12, 2018: Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD
May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001
Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder
Oct 18, 2016: Domain Therapeutics and Medicxi launch Mavalon Therapeutics, aimed at halting the progression of Parkinson’s disease
Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD
Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson’s disease with renewed support by The Michael J. Fox Foundation
Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results
Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study
Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Addex Therapeutics Ltd, H2 2018
Pipeline by Aevi Genomic Medicine Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Denovo Biopharma LLC, H2 2018
Pipeline by Domain Therapeutics SA, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Addex Therapeutics Ltd, H2 2018
Pipeline by Aevi Genomic Medicine Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Denovo Biopharma LLC, H2 2018
Pipeline by Domain Therapeutics SA, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Addex Therapeutics Ltd
Aevi Genomic Medicine Inc
AstraZeneca Plc
Denovo Biopharma LLC
Domain Therapeutics SA
Eli Lilly and Co
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Addex Therapeutics Ltd
Aevi Genomic Medicine Inc
AstraZeneca Plc
Denovo Biopharma LLC
Domain Therapeutics SA
Eli Lilly and Co
